---
title: "BridgeBio Pharma 表示，Acoramidis 在 30 個月期間將 CVM 或 CVH 的風險降低了 49%"
description: "BridgeBio Pharma Inc：ACORAMIDIS 在治療 ATTR-CM 患者的第一個月內開始減少累積心血管事件。BridgeBio Pharma Inc - ACORAMIDIS 在第 30 個月通過降低 CVM 或 CVH 風險達 49%"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/259221798.md"
published_at: "2025-09-28T15:18:56.000Z"
---

# BridgeBio Pharma 表示，Acoramidis 在 30 個月期間將 CVM 或 CVH 的風險降低了 49%

> BridgeBio Pharma Inc：ACORAMIDIS 在治療 ATTR-CM 患者的第一個月內開始減少累積心血管事件。BridgeBio Pharma Inc - ACORAMIDIS 在第 30 個月通過降低 CVM 或 CVH 風險達 49%

BridgeBio Pharma Inc :

-   ACORAMIDIS 在 ATTR-CM 患者的治療首月內開始降低累積心血管結果
-   BridgeBio Pharma Inc - ACORAMIDIS 在第 30 個月通過降低心血管事件或心血管住院風險達到 49% 的效果

### Related Stocks

- [BBIO.US - Bridgebio Pharma](https://longbridge.com/zh-HK/quote/BBIO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BridgeBio Pharma (BBIO) Receives a Buy from TD Cowen | TD Cowen analyst Tyler Van Buren has maintained a Buy rating on BridgeBio Pharma (BBIO) with a price target of $95.00. V | [Link](https://longbridge.com/zh-HK/news/275790948.md) |
| BridgeBio's oral drug improves growth in children with dwarfism in late-stage study | BridgeBio Pharma's experimental oral drug, infigratinib, has shown promising results in boosting growth rates in childre | [Link](https://longbridge.com/zh-HK/news/275756052.md) |
| BridgeBio Pharma Highlights Pipeline Progress and Patient Impact in New Corporate Presentation | BridgeBio Pharma Inc. has released a corporate presentation outlining its pipeline and strategy, focusing on first-in-cl | [Link](https://longbridge.com/zh-HK/news/272295165.md) |
| BridgeBio Pharma Publishes Study on Acoramidis for ATTR-CM | BridgeBio Pharma Inc. has published a study on acoramidis (Beyonttra) for treating transthyretin amyloid cardiomyopathy  | [Link](https://longbridge.com/zh-HK/news/265036749.md) |
| BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference | BridgeBio Pharma (NASDAQ:BBIO) presented at the J.P. Morgan Healthcare Conference, highlighting its ATTR-CM product, Att | [Link](https://longbridge.com/zh-HK/news/272361328.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。